Lumicera Health Services, a specialty pharmacy wholly owned by Navitus Health Solutions, announced today that it will be offering abiraterone acetate 250 mg tablets – the first landmark generic drug made available by CivicaScript™. Availability of this new generic medicine through Lumicera expands access for patients to clinically-proven, cost-effective drugs.
Abiraterone, which is used with steroid medication (prednisone) to treat prostate cancer that has spread to other parts of the body, is the first of six to 10 medicines that CivicaScript plans to initially develop to increase market competition and drive down price. The partnership between Lumicera and CivicaScript provides an opportunity to uniquely benefit payors and patients by furthering the shared commitment to transparency and drug affordability. This drug launch comes on the heels of Navitus Health Solutions announcing it has joined CivicaScript as a founding member.
"The lack of competition in the market is driving high-cost generic medicines, causing patients to ration or even entirely forgo their prescriptions," said Brent Eberle, Chief Pharmacy Officer of Navitus and Lumicera and CivicaScript Board Member. "We partnered with CivicaScript to address this problem. Providing abiraterone through our specialty pharmacy is our first big stride in making affordable generic medicines accessible to millions of patients who rely on these drugs to live their best lives."
CivicaScript was created in 2020 to bring affordable versions of common but high-priced generic medicines to market. The organization develops quality generic medicines through its trusted manufacturing partners, then works with like-minded payors, PBMs and pharmacies across the country to pass along the cost savings to their customers.
"This launch is just the beginning of our partnership with Lumicera and the critical work we're doing to ensure patients come before profits," Gina Guinasso, J.D., CivicaScript President. "Having abiraterone available to patients through Lumicera helps us advance our mission to make generic medicines affordable and available to everyone."
About Lumicera Health Services
Lumicera offers innovative specialty pharmacy solutions, framed in the core principles of transparency and stewardship. Lumicera is defining the "new norm" in specialty pharmacy to optimize patient well-being. We are dedicated to improving specialty pharmacy care, one patient at a time, through educational, clinical, financial and service excellence. Visit www.lumicera.com.
About Navitus Health Solutions
Navitus Health Solutions, owned by SSM Health and Costco Wholesale Corporation, is a disruptive industry alternative to traditional pharmacy benefit manager (PBM) models. As such, Navitus is committed to taking costs out of the drug supply chain - not shifting them - to make prescriptions more affordable for 8.7 million healthcare consumers through nearly 1,000 plan sponsors (i.e., employers, health plans, unions, governments, etc.). By returning 100% of rebates and discounts received and deploying a lowest-net-cost philosophy, Navitus helps reduce costs and improve member health. To learn more about Navitus, call 877.571.7500 or visit www.navitus.com. Follow Navitus on LinkedIn or Twitter to stay up-to-date on all the latest pharmacy benefit news, information and expert analysis.
CivicaScript is the Civica, Inc. operating unit dedicated to lowering the cost of select high-cost generic medicines at the pharmacy counter. Using a cost-plus and price-transparent model, CivicaScript, with its founding members including Blue Cross Blue Shield Association (BCBSA) and 18 independent BCBS health plans, Anthem, Health Care Service Corporation and EmsanaRx, will further transform the supply chain to lower the cost of prescription medicines to ensure that consumers benefit from these medicines at a fraction of their current cost. CivicaScript is a statutory public benefit company that is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information, visit civicascript.com.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.